- ►nih.gov - Free from Publisher AD Rao, N Kuhadiya, K Reynolds, VA … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A MEDLINE search (January 1966–July 2007) was
conducted to identify observational studies that examined the association
between combination therapy of sulfonylureas and metformin on risk of CVD ... Cited by 14 - Related articles - BL Direct - All 9 versions
GI Uwaifo, RE Ratner - The American Journal of Cardiology, 2007 - Elsevier Cardiovascular disease (CVD) burden remains the predominant cause of mortality
and morbidity in the United States and in most of the developed world. The
ongoing twin epidemics of obesity and type 2 diabetes mellitus provide a ... Cited by 9 - Related articles - All 32 versions
[CITATION] Drug Administration (2007) FDA briefing document. Joint meeting of the Endocrinologic …
DM Nathan - Archives of Internal Medicine, 2008 - archinte.highwire.org The worldwide epidemic of type 2 diabetes mellitus 1 has spurred the development
of numerous new medications directed at controlling glycemia. Since 1995, 6 new
classes of medications ( -glycosidase inhibitors, meglitinides, ... Cited by 3 - Related articles - All 5 versions
RB Goldberg - Current Opinion in Endocrinology, Diabetes and …, 2007 - journals.lww.com Recent findings: The thiazolidinedione class improves endothelial vasomotion,
inhibits inflammatory and procoagulant processes and has powerful
antiproliferative and antioxidant effects. Experimentally these agents ... Cited by 4 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org KH Kahler, M Rajan, GG Rhoads, MM Safford, … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS— A retrospective cohort study using data obtained
from the VHA Diabetes Epidemiology Cohort was used. Users of oral
antihyperglycemic therapy were classified into the following cohorts: ... Cited by 15 - Related articles - BL Direct - All 5 versions
E Fisman, M Motro, A Tenenbaum - Advances in cardiology, 2008 - content.karger.com Abstract Five types of oral antihyperglycemic drugs are currently approved for
the treatment of diabetes: biguanides, sulfonylureas, meglitinides, glitazones
and alpha-glucosidase inhibitors. We briefly review the cardiovascular ... Cited by 5 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org DJ Betteridge, RA DeFronzo, RJ Chilton - European Heart Journal, 2008 - Eur Soc Cardiology The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive)
remains the only completed cardiovascular (CV) outcomes study with a
thiazolidinedione. It has provided valuable information on the impact of ... Cited by 12 - Related articles - BL Direct - All 10 versions
SS Lund, L Tarnow, CD Stehouwer, CG … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2
diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular
protective potentials. In non-obese patients with T2DM, insulin ... Cited by 11 - Related articles - All 4 versions
- ►eje-online.org SS Lund, L Tarnow, CDA Stehouwer, CG … - European Journal of Endocrinology, 2008 - EFES Results: Levels of tumour necrosis factor- , plasminogen activator inhibitor-1
antigen, tissue-type plasminogen activator antigen, von Willebrand factor,
soluble intercellular adhesion molecule-1 and soluble E-selectin were ... Cited by 12 - Related articles - BL Direct - All 6 versions
